Global Molecular Cytogenetics Market Trends 2019 | Segmentation, Outlook, Industry Report to 2025

The global molecular cytogenetics market is estimated to grow at a CAGR of more than 6% during the forecast period. Increasing US FDA approvals for personalized medicines supporting the growth in genomics researches. For instance, as per the Personalized Medicine Coalition, in 2018, 25 of the 59 new molecular entities (NMEs) FDA approved are personalized medicines, which is 42% of all new drug approvals. The Coalition classified 34% of NMEs as personalized medicines in 2017, 28% in 2015; 27% in 2016. The US FDA is making efforts to facilitate access to genomic testing and integrating real-world evidence into its regulatory framework. As a result, the FDA, for the first time, authorized the marketing of cancer-related genetic tests and pharmacogenetics were allowed to sell directly to the consumers.

Request a Free Sample of our Global Molecular Cytogenetics Market: https://www.omrglobal.com/request-sample/molecular-cytogenetics-market

This results in the development of personalized medicine as an emerging practice of medicine that utilizes the genetic profile of an individual which supports to make appropriate decisions regarding prevention, diagnosis, and treatment of the condition. Gaining complete knowledge of a patient's genetic profile assists doctors to opt for the proper therapy or medication. In addition, it allows to administer drugs or therapy by utilizing the proper regimen or dose. 1000 Genomes Project is an effort that comprises genome sequencing of at least a thousand people from across the globe to develop the most comprehensive and medically relevant picture of human genetic variation.

This initiative intends to make accessible genomic data easily from international research institutions. The major support for the project is offered by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), Wellcome Trust Sanger Institute in Hinxton, England, and the Beijing Genomics Institute, Shenzhen (BGI Shenzhen) in China. This project shows a rising focus on genomic researches across the globe, which in turn, is supporting the development of personalized medicines, which thereby attributing to positive market growth. As a conventional technique, cytogenetic analysis is used to diagnose chromosome instability and may specify the presence of a genetic disorder or malignancy. It is one of the first techniques used for precision medicine.

Cytogenetic analysis is significantly applied to offer crucial diagnostic, prognostic, and therapeutic information for the development of cancer precision medicine and research. A combination of molecular biology and cytogenetics methods created an opportunity in the field of oncology, as well as to develop precision medicine for cancer patients. Currently, a combination of high-throughput technologies are used in clinical laboratories for identification of noncoding RNAs, deregulated cellular pathways, protein expression profiles, and mutation signatures, with effect in the prediction and early diagnosis of therapeutic response in cancer patients.

Molecular cytogenetics is a major addition to traditional cytogenetics, as it enables more accurate identification of clinically relevant genetic abnormalities. This is achieved with the monitoring of specific DNA sequences in the nuclei and chromosomes of cancer cells. The FISH technique is being the most commonly used technique in molecular cytogenetics. It has major benefits in clinical practice owing to its ability to examine chromosomal alterations in nondividing cells, specifically directly in tissue sections and cytology preparations. Further, increasing advances in molecular cytogenetics techniques are creating a remarkable growth opportunity for the adoption of molecular cytogenetics in precision medicine, which in turn, is expected to drive the global molecular cytogenetics market.

A full Report of Global Molecular Cytogenetics Market is Available at: https://www.omrglobal.com/industry-reports/molecular-cytogenetics-market

Molecular Cytogenetics Market Segmentation

By Product

• Consumables
• Software and Services
• Instruments

By Application

• Cancer
• Genetic Disorders
• Personalized Medicine

By Technique

• Fluorescence in Situ Hybridization (FISH)
• Comparative Genomic Hybridization (CGH)
• Others (Karyotyping and Next-Generation Sequencing)

Molecular Cytogenetics Market – Segment by Region

North America

• The US
• Canada
Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

Company Profiles

• Abbott Laboratories, Inc.
• ADS Biotec Inc.
• Agilent Technologies, Inc.
• Applied Spectral Imaging
• BioDot Inc.
• Biological Industries Israel Beit Haemek Ltd.
• Bio-Rad Laboratories, Inc.
• Danaher Corp.
• Euroclone S.p.A.
• F. Hoffmann La-Roche AG
• FUJIFILM Irvine Scientific
• Illumina, Inc.
• Laboratory Imaging s.r.o.
• Leica Biosystems
• MetaSystems Hard & Software GmbH
• Nikon Corp.
• Oxford Gene Technology Ltd.
• PAN-Biotech GmbH
• Perkinelmer, Inc.
• Tecan Group Ltd.
• Thermo Fisher Scientific Inc.

Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/molecular-cytogenetics-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.